| Description |
Blarcamesine (AVex-73;AE-37) is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome[1].
|
| Related Catalog |
|
| Target |
Sigma-1 receptor, muscarinic receptor[1]
|
| In Vivo |
Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration[1]. Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice[1]. Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response[1]. Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice[1]. Animal Model: Female Mecp2tm1.1Bird/J HET (C57 background) mice[1] Dosage: 10 mg/kg, 30 mg/kg Administration: Oral administration, daily, for 6.5 weeks Result: Reverse the deficits observed in the HET animals.
|
| References |
[1]. Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796.
|
